Benitec Biopharma Inc (BNTC) is trading up at $8.82 (+3.76%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2019Jun 2019 | FY2020Jun 2020 | FY2021Jun 2021 | FY2022Jun 2022 | FY2023Jun 2023 | FY2024Jun 2024 | FY2025Jun 2025 | FY2026Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $12.2M | $102.0K | $59.0K | $73.0K | $75.0K | $0 | — | — |
| Growth (year over year) | — | −99.2% | −42.2% | +23.7% | +2.7% | −100.0% | — | — |
| Operating income | $2.58M | −$8.28M | −$13.6M | −$17.9M | −$19.1M | −$22.5M | −$41.8M | −$51.2M |
| Operating margin | 21.2% | −8118.6% | −23044.1% | −24457.5% | −25441.3% | — | — | — |
| Net income | $2.61M | −$8.27M | −$13.9M | −$18.2M | −$19.6M | −$21.8M | −$37.9M | −$45.5M |
| Net margin | 21.4% | −8111.8% | −23528.8% | −24942.5% | −26082.7% | — | — | — |
| EPS (diluted) | $3.05 | −$8.10 | −$3.23 | −$37.88 | −$14.12 | −$1.22 | −$1.05 | −$0.98 |
| Balance sheet | ||||||||
| Cash and equivalents | $15.7M | $9.80M | $19.8M | $4.06M | $2.48M | $50.9M | $97.7M | $180.0M |
| Total assets | $19.2M | $11.6M | $21.4M | $5.97M | $4.46M | $52.2M | $99.6M | $182.6M |
| Total liabilities | $2.64M | $1.35M | $1.37M | $3.09M | $4.26M | $4.96M | $2.30M | $5.61M |
| Shareholders' equity | $16.6M | $10.2M | $20.0M | $2.88M | $202.0K | $47.2M | $97.3M | $177.0M |
| Cash flow | ||||||||
| Operating cash flow | $4.79M | −$7.54M | −$12.8M | −$15.9M | −$18.0M | −$19.4M | −$23.6M | −$16.5M |
| Capital expenditure | $404.0K | $95.0K | $221.0K | $13.0K | $1.00K | $179.0K | $18.0K | $105.0K |
| Free cash flow | $4.39M | −$7.63M | −$13.1M | −$15.9M | −$18.0M | −$19.6M | −$23.6M | −$16.6M |
| Q1 FY25Sep 2024 | Q2 FY25Dec 2024 | Q3 FY25Mar 2025 | Q4 FY25†Jun 2025 | Q1 FY26Sep 2025 | Q2 FY26Dec 2025 | Q3 FY26Mar 2026 | Q4 FY26†Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | — | $0 | $0 | $0 | — |
| Operating income | −$5.79M | −$10.8M | −$15.3M | −$9.83M | −$9.80M | −$13.4M | −$13.6M | −$14.4M |
| Net income | −$5.06M | −$9.55M | −$14.5M | −$8.80M | −$8.96M | −$11.8M | −$11.9M | −$12.8M |
| EPS (diluted) | −$0.18 | −$0.26 | −$0.38 | −$0.23 | −$0.22 | −$0.26 | −$0.24 | −$0.26 |
| Balance sheet | ||||||||
| Cash and equivalents | $67.8M | $78.3M | $103.6M | $97.7M | $94.5M | $188.8M | $184.8M | $180.0M |
| Total assets | $68.8M | $79.1M | $105.2M | $99.6M | $96.0M | $190.7M | $187.0M | $182.6M |
| Total liabilities | $4.59M | $3.13M | $7.64M | $2.30M | $2.43M | $3.32M | $3.67M | $5.61M |
| Shareholders' equity | $64.2M | $75.9M | $97.6M | $97.3M | $93.6M | $187.4M | $183.3M | $177.0M |
| Cash flow | ||||||||
| Operating cash flow | −$4.59M | −$7.70M | −$3.09M | −$8.21M | −$3.35M | −$3.78M | −$4.45M | −$4.94M |
| Capital expenditure | — | — | $6.00K | $0 | — | — | $15.0K | $79.0K |
| Free cash flow | — | — | −$3.09M | −$8.21M | — | — | −$4.47M | −$5.02M |
From Benitec Biopharma Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in June. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Benitec Biopharma Inc in our feed yet.